BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sahutoglu T, Basturk T, Sakaci T, Koc Y, Ahbap E, Sevinc M, Kara E, Akgol C, Caglayan FB, Unsal A, Daha MR. Can eculizumab be discontinued in aHUS?: Case report and review of the literature. Medicine (Baltimore) 2016;95:e4330. [PMID: 27495036 DOI: 10.1097/MD.0000000000004330] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Ricklin D, Mastellos DC, Reis ES, Lambris JD. The renaissance of complement therapeutics. Nat Rev Nephrol 2018;14:26-47. [PMID: 29199277 DOI: 10.1038/nrneph.2017.156] [Cited by in Crossref: 196] [Cited by in F6Publishing: 183] [Article Influence: 39.2] [Reference Citation Analysis]
2 Fayek SA, Allam SR, Martinez E, Pan G, Dao A, Rofaiel G. Atypical Hemolytic Uremic Syndrome After Kidney Transplantation: Lessons Learned From the Good, the Bad, and the Ugly. A Case Series With Literature Review. Transplant Proc 2020;52:146-52. [PMID: 31924403 DOI: 10.1016/j.transproceed.2019.10.015] [Reference Citation Analysis]
3 García-martín E, Manrique-rodríguez S, Martínez Fernández-llamazares C, Goicoechea-diezhondino M, Álvarez-blanco O, García-morín M, Sanjurjo-sáez M. Variability in management and outcomes of therapy with eculizumab in atypical hemolytic uremic syndrome. Expert Opinion on Orphan Drugs 2019;7:525-33. [DOI: 10.1080/21678707.2019.1703108] [Reference Citation Analysis]
4 Baines AC, Brodsky RA. Complementopathies. Blood Rev 2017;31:213-23. [PMID: 28215731 DOI: 10.1016/j.blre.2017.02.003] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 10.8] [Reference Citation Analysis]
5 Neumann T, Plis A, Weigel M, Stracke S, Friesecke S, Stecher SS, Schneidewind L, Busemann C, Schmidt CA, Krüger WH. No Relapse of Calcineurin Inhibitor-Associated Thrombotic Microangiopathy after Discontinuation of Eculizumab. Acta Haematol 2017;138:194-7. [PMID: 29136616 DOI: 10.1159/000481724] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
6 Zhang K, Lu Y, Harley KT, Tran MH. Atypical Hemolytic Uremic Syndrome: A Brief Review. Hematol Rep 2017;9:7053. [PMID: 28626544 DOI: 10.4081/hr.2017.7053] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
7 Jiao L, Li H, Guo S. Eculizumab treatment for myasthenia gravis subgroups: 2021 update. J Neuroimmunol 2022;362:577767. [PMID: 34823117 DOI: 10.1016/j.jneuroim.2021.577767] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Klämbt V, Gimpel C, Bald M, Gerken C, Billing H, Loos S, Hansen M, König J, Vinke T, Montoya C, Sperandio BL, Kirschstein M, Hennies I, Pohl M, Häffner K. Different approaches to long-term treatment of aHUS due to MCP mutations: a multicenter analysis. Pediatr Nephrol 2021;36:463-71. [PMID: 32715379 DOI: 10.1007/s00467-020-04714-0] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Kim SH, Kim HY, Kim SY. Atypical hemolytic uremic syndrome and eculizumab therapy in children. Korean J Pediatr 2018;61:37-42. [PMID: 29563942 DOI: 10.3345/kjp.2018.61.2.37] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
10 Higuero Saavedra V, González-Calle V, Sobejano E, Sebastiá J, Cabrero M, Bastida JM, Puig N, Ocio EM, Mateos MV. Drug-induced Thrombotic Microangiopathy During Maintenance Treatment in a Patient With Multiple Myeloma. Hemasphere 2019;3:e192. [PMID: 31723829 DOI: 10.1097/HS9.0000000000000192] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
11 Vitkauskaitė M, Vinikovas A, Miglinas M, Rimševičius L, Čerkauskaitė A, Mačionienė E, Ašakienė E. Complement inhibitor eculizumab in thrombotic microangiopathy: Single‐center case series. Clinical Case Reports 2022;10. [DOI: 10.1002/ccr3.5573] [Reference Citation Analysis]